European Journal of Pediatrics

, Volume 161, Issue 1, pp S2–S9 | Cite as

Historical highlights and unsolved problems in glycogen storage disease type 1

  • Shimon W. Moses
Original Paper


Thirty-three years after Von Gierke described the first patient with glycogen storage disease type 1 (GSD1) in 1929, the Coris detected glucose-6-phosphatase (G6Pase) deficiency. The first mutation of this enzyme was identified 41 years later and subsequently the gene was mapped to chromosome 17q21, its enzyme topology defined, a nine transmembrane helical model suggested, an enzyme deficient knockout mouse created and by infusing an adenoviral vector associated murine G6Pase gene, correction of the clinical and laboratory abnormalities was observed. A similar successful gene transfer has been performed in enzyme deficient canine puppies. To explain the function of the G6Pase complex, a multicomponent translocase catalytic model has been proposed in which different transporters shuttle glucose-6-phosphate (G6P), inorganic phosphate (Pi) and glucose across the microsomal membrane. It was suggested that GSD1b patients suffered from a G6P transporter (G6PT) defect and the first mutation in the G6PT gene subsequently recognised. The gene mapped to chromosome 11q23 and its structural organisation was defined which showed a close functional linkage between G6PT and hydrolysis. Nordlie identified the first patient with Pi transport deficiency (GSD1c). However putative GSD1c and 1d patients based on kinetic studies were found to harbour mutations in the G6PT gene so that GSD1 patients are presently divided into 1a and non-1a. G6PT deficient patients suffer from numerical and functional leucocyte defects. A mRNA leucocyte G6PT deficiency has been suggested to account for the glucose phosphorylation and subsequent calcium sequestration defects observed in theses cells. Inflammatory bowel disease which occurs frequently in GSD non-1a patients has been related to their leucocyte abnormalities. Dietary management of GSD1 patients, designed to maintain a normal blood glucose level can be achieved during the night by nocturnal gastric infusions of glucose-containing solution or by the administration of uncooked cornstarch around the clock or by a combination of both. Both therapeutic modalities, if conducted in a meticulous manner, have a major impact on the quality of life, prevention of complications and subsequent prognosis. Open questions relate to the source of endogenous glucose production in GSD1 patients which increases as a function of age from 50% to 100% of normal, concomitant with an improvement in the patients fasting tolerance. Several complications, the nature of which is incompletely understood, tend to occur after the first decade: Liver adenomata with a small risk of transforming into hepatoma, progressive renal disease, which may be related to the hyperlipidaemia observed in this disease, often leading to end stage renal failure, osteopenia apparently based on high bone turnover, growth retardation and delayed puberty.Conclusion: this review highlights the present knowledge of glycogen storage disease type 1 and subtypes, discussing unsolved questions, which reflect the limitation of our knowledge in the understanding of this intriguing group of diseases.


Complications Glycogen storage disease type 1 Subtypes Treatment 



bone mineral density






glucose-6-phosphate transporter protein


glycogen storage disease


inflammatory bowel disease


inorganic phosphate


  1. 1.
    Alaupoviv P, Fernandes J (1985) The serum apoliporotein profiles of patients with glucose-6-phosphatase deficiency. Pediatr Res 19: 380–384CrossRefGoogle Scholar
  2. 2.
    Alshak NS, Cocjin J, Podesta L, van de Velde R, Makowka L, Rosenthal P, Geller SA (1994) hepatocellular adenoma in glycogen storage disease type IV. Arch Pathol Lab Med 118: 88–91PubMedGoogle Scholar
  3. 3.
    Ament ME, Ochs MD (1973) Gastrointestinal manifestations of chronic granulomatous disease. N Engl J Med 288: 382–387PubMedCrossRefGoogle Scholar
  4. 4.
    Annabi B, Hiraiwa H, Mansfield BC, Lei KJ, Ubagai T et al (1998) The gene for glycogen storage disease type 1b maps to chromosome 11q23. Am J Hum Genet 62: 400–405PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Arion WJ, Lange AJ, Walls HE, Ballas LM (1980) Evidence for the participation of independent translocases for phosphate and glucose-6-phosphate in the microsomal glucose-6-phosphatase system. J Biol Chem 255: 10396–10406PubMedGoogle Scholar
  6. 6.
    Banhegyi G, Marcolongo P, Fulceri R, Hinds C, Burchell A, Benedetti A (1997) demonstration of metabolically active glucose-6-phosphate pool in the lumen of liver microsome vesicles. J Biol Chem 272: 13584–135490PubMedCrossRefGoogle Scholar
  7. 7.
    Bashan N, Potashnik R, Peist A, Peleg N, Moran A, Moses SW (1993) Deficient glucose phosphorylation as a common denominator and its relation to abnormal leucocyte function in glycogen storage disease type 1b patients. Eur J Pediatr 152[Suppl 1]: S44-S48PubMedCrossRefGoogle Scholar
  8. 8.
    Beaty RM, Jackson M, Kishnani PS, Faulkner E, Van Camp S et al (2000) Gene therapy with adenoassociated virus (AVV) vectors in canine glycogen storage disease type 1a. Am J Hum Genet 67[Suppl 2]: 432Google Scholar
  9. 9.
    Beaudet AL, Anderson DC, Michels VV, Arion WJ, Lange AJ (1980) Neutropenia and impaired neutrophil migration in type 1b glycoegn storage disease. J Pediatr 97: 906–910PubMedCrossRefGoogle Scholar
  10. 10.
    Bianchi L (1993) Glycogen storage disease 1 and hepatocellular tumours. Eur J Pediatr 152[Suppl 1]: S63-S70PubMedCrossRefGoogle Scholar
  11. 11.
    Burchell A (1998) A reevaluation of GLUT 7. Biochem J 331: 973PubMedCentralPubMedGoogle Scholar
  12. 12.
    Burchell A, Waddell I (1991) The molecular basis of the hepatic microsomal glucose-6-phosphatase system. Biochim Biophys Acta 1092: 129–137PubMedCrossRefGoogle Scholar
  13. 13.
    Burchell A, Waddell I, Zomerschoe AG, Voice MW (1992) Cloning and expression of hepatic microsomal glucose transport protein. Comparison with liver plasma glucose transport protein GLUT 2. Biochem J 286: 173–177PubMedCentralPubMedGoogle Scholar
  14. 14.
    Chen YT (1991) Type 1 glycogen storage disease: kidney involvement, pathogenesis and treatment. Pediatr Nephrol 5: 71–76PubMedCrossRefGoogle Scholar
  15. 15.
    Chen YT, Cornblath M, Sidbury JB (1984) Cornstarch therapy in type 1 glycogen storage disease. N Engl J Med 310: 171–175PubMedCrossRefGoogle Scholar
  16. 16.
    Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB (1988) Renal disease in type 1 glycogen storage disease. N Engl J Med 318: 7–11PubMedCrossRefGoogle Scholar
  17. 17.
    Chen YT, Bazarre C, Lee MM, Sidbury JB, Coleman RA (1993) Type 1 glycogen storage disease: nine years of management with cornstarch. Eur J Pediatr 152[Suppl 1]: S56-S59PubMedCrossRefGoogle Scholar
  18. 18.
    Cori GT, Cori CF (1952) Glucose-6-phosphatase in the liver in glycogen storage disease. J Biol Chem 199: 661–667PubMedGoogle Scholar
  19. 19.
    Emmett M, Narias RG (1978) Renal transplantation in type 1 glycogenosis: failure to improve glucose metabolism. JAMA 239: 1642–1644PubMedCrossRefGoogle Scholar
  20. 20.
    Fata F, Myers P, Addeo J, Grimberg M, Nawabi I, Cappel MS (1997) Cyclic neutropenia in Crohn's ileocolitis: efficacy of granulocyte colony-stimulating factor. J Clin Gastroenterol 24: 253–256PubMedCrossRefGoogle Scholar
  21. 21.
    Fernandes J (1974) The effect of disaccharides on the hyperlacticacidaemia of glucose-6-phosphatase deficient children. Acta Paediatr Scand 63: 695–698PubMedCrossRefGoogle Scholar
  22. 22.
    Gerin I, Veiga-da-Cunha M, Achoury Y, Collet JF, Van Schaftingen E (1997) Sequence of a putative glucose-6-phosphate translocase mutated in glycogen storage disease type 1b. FEBS Lett 419: 235–238PubMedCrossRefGoogle Scholar
  23. 23.
    Gitzelmann R, Bosshard NU (1993) Defective neutrophil and monocyte functions in glycogen storage disease type 1b: a literature review. Eur J Pediatr 152[Suppl 1]: S33-S38PubMedCrossRefGoogle Scholar
  24. 24.
    Goans RE, Weiss GH, Viera NE, Sidbury JB, Abrams SA, Yergey AL (1996) Calcium kinetics in glycogen storage disease type 1a. Calcif Tissue Int 59: 449–453.PubMedCrossRefGoogle Scholar
  25. 25.
    Green H, Slonim AE, Burr IM, Moran JR (1976) Continuous nocturnal intragastric feeding for the management of type 1 glycogen storage disease. N Engl J med 294: 423–425CrossRefGoogle Scholar
  26. 26.
    Guillam MT, Burcelin R, Thorens B (1998) Normal hepatic glucose production in the absence of GLUT 2 reveals an alternative pathway for glucose release from hepatocytes. proc Natl Acad Sci USA 95: 12317–12321PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Havel RJ, Balasse EO, Williams HE, Kane JP, Segel N (1969) Splanchnic metabolism in Von Gierke's disease (glycogenosis type 1). Trans Assoc Am Phys 82: 305–323PubMedGoogle Scholar
  28. 28.
    Hers HG, Van Hoof F, De Barsy T (1989) Glycogen storage disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 425–452Google Scholar
  29. 29.
    Hiraiwa H, Pan CJ, Baochuan L, Moses SW, Chou YC (1999) Inactivation of the glucose-6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 274: 5532–5536PubMedCrossRefGoogle Scholar
  30. 30.
    Howell RR, Stevenson RE, Ben-Menahem Y, Phyliky RL, Berry H (1976) Hepatic adenomata with type 1 glycogen storage disease. JAMA 236: 1481–1484PubMedCrossRefGoogle Scholar
  31. 31.
    Huismans D, Rake JP, Visser G, Piers DA, Smith GPA (1997) Decreased bone mineral density in glycogen storage disease type 1. J Inherit Metab Dis 20[Suppl 1]: 81Google Scholar
  32. 32.
    Ihara K, Nomura A, Hikino S, Takada H, Hara T (2000) Quantitative analysis of glycose-6-phosphate translocase gene expression in various human tissues and haemopoetic progenitor cells. J Inherit Metab Dis 23: 583–592PubMedCrossRefGoogle Scholar
  33. 33.
    Kalhan SC, Gilfillan C, Tserng KY, Savin SM (1982) Glucose production in type 1 glycogen storage disease. J Pediatr 101: 159–160PubMedGoogle Scholar
  34. 34.
    Keane WF (1996) Lipids and progressive renal failure. Wien Klin Wochenschr 14: 420–424Google Scholar
  35. 35.
    Keane WF (2000) The role of lipids in renal disease: future challenges. Kidney Int 57: S27-S31CrossRefGoogle Scholar
  36. 36.
    Kelsch RC, Oliver WJ (1969) Studies on dietary correction of metabolic abnormalities in hepatorenal glycogenesis. Pediatr Res 3: 160–170PubMedCrossRefGoogle Scholar
  37. 37.
    Kilpatrick I, Garty B-Z, Lundquist KF, Hunter K, Stanley CA, Baker L, Douglas SD, Korchak HM (1990) Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest 86: 196–202PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Lee PJ, Patel JS, Fewtrell M, Leonard JV, Bishop NJ (1995) Bone mineralisation in type 1 glycogen storage disease. Eur J Pediatr 54: 483–487CrossRefGoogle Scholar
  39. 39.
    Leese T, Farges O, Bismuth H (1988) Liver cell adenomas: a 12-year surgical experience from a specialist hepatobiliary unit. Ann Surg 205: 558–561CrossRefGoogle Scholar
  40. 40.
    Leffert HL, Koch KS, Moran T, Rubalcava B (1979) Hormonal control of liver regeneration. Gastroenterology 760: 1470–1482Google Scholar
  41. 41.
    Lei KJ, Chen YT, Chen H, Wong LJC, Liu JL et al (1995) Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet 57: 766–771PubMedCentralPubMedGoogle Scholar
  42. 42.
    Lei KJ, Chen H, Pan CJ, Ward JM, Mosinger B Jr et al (1996) Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type 1a mouse. Nat Genet 13: 203–209PubMedCrossRefGoogle Scholar
  43. 43.
    Levy E, Thibault LA, Roy CC, Bendayan M, Lepage G (1988) Circulating lipids and lipoproteins in glycogen storage disease type 1 with nocturnal gastric feeding. J Lipid Res 29: 215–226PubMedGoogle Scholar
  44. 44.
    Limmer J, Fleig WE, Leupold D, Bittner R, Ditschuneit H, Beger HG (1988) Hepatocellular carcinoma in type 1 glycogen storage disease. Hepatology 8: 531–537PubMedCrossRefGoogle Scholar
  45. 45.
    Lin B, Hiraiwa H, Pan CJ, Nordlie RC, Chou JY (1999) Type 1c glycogen storage disease is not caused by mutations in the glucose-6-phosphate transporter gene. Hum Genet 105: 515–517PubMedCrossRefGoogle Scholar
  46. 46.
    Mason DH, Anderson DH (1955) Glycogen disease of the liver (von Gierke's disease) with hepatoma: case report with metabolic studies. Pediatrics 16: 785–799PubMedGoogle Scholar
  47. 47.
    Narisawa K, Igarashi Y, Otomo H, Tada K (1978) A new variant of glycogen storage disease type 1 probably due to a defect in the glucose-6-phosphate transport system. Biochem Biophys Res Commun 83: 1360–1364PubMedCrossRefGoogle Scholar
  48. 48.
    Nordlie RC, Sukalski KA, Munoz JM, Baldwin JJ (1983) Type 1c, a novel glycogenosis. Underlying mechanism. J Biol Chem 258: 9739–9744PubMedGoogle Scholar
  49. 49.
    Nordlie RC, Scott HM, Waddell I, Hume R, Burchell A (1992) Analysis of human hepatic microsomal glucose-6-phosphatase in clinical conditions where the T2 pyrophosphate/phosphate transport protein is absent. Biochem J 281: 859–863PubMedCentralPubMedGoogle Scholar
  50. 50.
    Oda H, Keane WF (1999) Recent advances in statins and the kidney. Kidney Int 56[Suppl 7]: S2-S5CrossRefGoogle Scholar
  51. 51.
    Ozen H, Ciliv G, Kocak N, Satik IN, Yuce A, Gorokan F (2000) Short term effect of captopril on microalbuminuria in children with glycogen storage disease type 1a. J Inherit Metab Dis 23: 459–463PubMedCrossRefGoogle Scholar
  52. 52.
    Pan CJ, Lei KJ, Annabi B, Hemrika W, Chou JY (1998) Transmembrane topology of glucose-6-phosphatase. J Biol Chem 273: 6144–6148PubMedCrossRefGoogle Scholar
  53. 53.
    Parker P, Burr I, Slonim A, Gishan FK, Green H (1981) Regression of hepatic adenoma in type 1a glycogen storage disease with dietary therapy. Gastroenterology 81: 534–536PubMedGoogle Scholar
  54. 54.
    Powell RC, Wentworth SM, Brandt JK (1981) Endogenous glucose production in type 1 glycogen storage disease. Metabolism 30: 443–450PubMedCrossRefGoogle Scholar
  55. 55.
    Roe TF, Thomas DW, Gisanz V, Isaacs H Jr, Atkinson JB (1986) Inflammatory bowel disease in glycogen storage disease type 1b. J Pediatr 109: 55–59PubMedCrossRefGoogle Scholar
  56. 56.
    Roe TF, Coates TD, Thomas DW, Miller JH, Gilsanz V (1992) Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type 1b with colony stimulating factors. N Engl Med 326: 1666–1669CrossRefGoogle Scholar
  57. 57.
    Rother KI, Schwenk WF (1995) Glucose production in glycogen storage disease 1 is not associated with increased cycling through hepatic glycogen. Am J Physiol 269: E774-E778PubMedGoogle Scholar
  58. 58.
    Sadeghi-Nejad A, Hochmann H, Senior B (1974) Studies in type 1 glycogenosis of the liver. J Pediatr 85: 49–54PubMedCrossRefGoogle Scholar
  59. 59.
    Schoenheimer R (1929) Über eine eigenartige Störung des Kohlenhydratstoffwechsels. Z. Physiol Chem 182: 149–151Google Scholar
  60. 60.
    Schulze H, Nolte B, Kannler R (1986) Evidence for changes in the conformational status of rat liver microsomal glucose-6-phosphate: phosphohydrolase during detergent dependent modification. J Biol Chem 261: 16571–16578PubMedGoogle Scholar
  61. 61.
    Selby R, Starzl TE, Yunis E, Todo S, Tzakis AG, Brown BI, Kendall RS (1993) Liver transplantation for type 1 and type IV glycogen storage disease. Eur J Pediatr 152[Suppl 1]: S71-S76PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Senior B, Loridan L (1968) Studies of liver glycogenosis, with particular reference to the metabolism of intravenously administered glycerol. N Engl J med 279: 958–970PubMedCrossRefGoogle Scholar
  63. 63.
    Shanahan F, Bernstein CN (1993) Odd forms of inflammatory bowel disease: what can they tell us?, Gastroenterology 104: 327–329PubMedGoogle Scholar
  64. 64.
    Smith GPA (1993) results of the European Study on Glycogen Storage Type 1. Eur J Pediatr 152 [Suppl 1]: S52-S55CrossRefGoogle Scholar
  65. 65.
    Srivastava T, Alon US (1999) Biphosphonates: from grand-parents to gradchildren. Clin Pediatr 38: 687–702CrossRefGoogle Scholar
  66. 66.
    Starzl TF, Putman CV, Porter KA, Halgrimson CG, Corman J et al (1973) Portal diversion for the treatment of glycogen storage disease in humans. Ann Surg 178: 525–539PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Steim H, Zollinger HU (1967) Tödliche Schrumpfniere bei Glykogenspeicherkrankheit typ Von Gierke. Klin Wochenschr 45: 295–299PubMedCrossRefGoogle Scholar
  68. 68.
    Talente GM, Coleman GA, Alter C, Baker L, Brown BI, Cannon RA et al (1994) Glycogen storage disease in adults. Ann Intern Med 120: 218–226PubMedCrossRefGoogle Scholar
  69. 69.
    Tsalikian E, Simmons P, Gerich JE, Howard C, Haymond MW (1984) Glucose production and utilisation in children with glycogen storage disease type 1. Am J Physiol 247: E513-E519PubMedGoogle Scholar
  70. 70.
    Van Hoof F, Hue L, De Barsy T, Jacquemin P, Devos P, Hers HG (1972) Glycogen storage diseases. Biochimie 54: 745–752PubMedCrossRefGoogle Scholar
  71. 71.
    Veiga-da-Cunha M, Gerin M, Chen YT, Lee PJ, Leonard JV, Maire I, Wendel U, Vikkula M, Van Schaftingen E (1999) The putative glucose-6-phosphatase gene is mutated essentially in all cases of glycogen storage disease type 1 non-a. Eur J Hum Genet 7: 717–723PubMedCrossRefGoogle Scholar
  72. 72.
    Verhoeven AJ, Visser G, Zwieten RV, Gruszczynska B, Pol-The BT, Smith GPA (1999) A convenient diagnostic function test of peripheral blood neutrophils in glycogen storage disease 1b. Pediatr Res 45: 881–885PubMedCrossRefGoogle Scholar
  73. 73.
    Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, Ullrich K, Smit GPA (2000) Neutropenia, neutrophil dysfunction and inflammatory bowel disease in glycogen storage disease type 1b. J Pediatr 137: 187–191PubMedCrossRefGoogle Scholar
  74. 74.
    Von Gierke E (1929) Hepato-nephro-megalia-glycogenica (Glykogenspeicherkrankheit der Leber und Nieren). Beitr Pathol Anat 82: 497–513Google Scholar
  75. 75.
    Waddell I, Scott H, Grant A, Burchell A (1991) Identification and characterisation of a rat microsomal glucose transport protein. Glucose-6-phosphatase T3? Biochem J 285: 173–177Google Scholar
  76. 76.
    Wallace JL, McKnight W, Asfaha S, Lin DY (1998) Reduction od acute and reactive colitis in rats by an inhibitor of neutrophil activation. Am J Physiol 274: G802-G808PubMedGoogle Scholar
  77. 77.
    Weinstein DA, Somer MJG, Wolsdorf JI (2000) Inverse correlation between urinary citrate excretion and age in type 1a glycogen storage disease: pathophysiology and implications for renal complications. Pediatr Res 47[Suppl 454]: A2686Google Scholar
  78. 78.
    Wolsforf JI, Crigler JF Jr (1999) Effect of continuous glucose therapy begun in infancy on the long term clinical course of patients with type 1 glycogen storage disease. J Pediatr Gastroenterol Nutr 29: 136–143.CrossRefGoogle Scholar
  79. 79.
    Zingone A, Hiraiwa H, Pan CJ, Lin B, Chen H, Ward JM, Chou YC (2000) Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J Biol Chem 275: 828–832PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • Shimon W. Moses
    • 1
  1. 1.Department of PaediatricsSoroka Medical CentreBeershevaIsrael

Personalised recommendations